sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Unknown 14 enrolled Northwestern University National Cancer Institute (NCI) · collab Vasgene Therapeutics, Inc · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this phase II, single-arm, open-label, three center study is to evaluate the efficacy, safety, and tolerability of sEphB4-HSA in patients with mCRPC (metastatic castration-resistant prostate cancer). The study drug, sEphB4-HAS, is a form of protein that has not been approved for sale by the United States Food and Drug Administration (FDA). The study drug prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.

Timeline

Start: 2019-09-20
Primary completion: 2021-02-05
Completion: 2022-06-30

Outcome

Missed primary endpoint

paper No patient had a confirmed PSA response, and the study was stopped for futility. PMID 36210299 ↗

Publications

VanderWeele DJ, Kocherginsky M, Munir S, Martone B, Sagar V, Morgans A, Stadler WM, Abdulkadir S, Hussain M. A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Dec;20(6):575-580. doi: 10.1016/j.clgc.2022.08.012. Epub 2022 Sep 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	sEphB4-HSA	Protein / enzyme biologic	1000 mg	Intravenous